These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18324639)

  • 1. The therapeutic potential of the proteasome in leukaemia.
    McCloskey SM; McMullin MF; Walker B; Irvine AE
    Hematol Oncol; 2008 Jun; 26(2):73-81. PubMed ID: 18324639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition as novel treatment strategy in leukaemia.
    Vink J; Cloos J; Kaspers GJ
    Br J Haematol; 2006 Aug; 134(3):253-62. PubMed ID: 16787504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors in pediatric cancer treatment.
    Bachmann AS
    Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
    Tahmatzopoulos A; Gudegast C; Stöckle M; Wullich B; Unteregger G; Zwergel U; Zwergel T
    Aktuelle Urol; 2004 Nov; 35(6):491-6. PubMed ID: 15526229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition in multiple myeloma.
    Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
    Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
    Kelley TW; Alkan S; Srkalovic G; Hsi ED
    Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitors in lung cancer.
    Scagliotti G
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proteasome inhibitors].
    Hatake K; Mishima Y; Terui Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
    Mitsiades CS
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib as a potential treatment for prostate cancer.
    Papandreou CN; Logothetis CJ
    Cancer Res; 2004 Aug; 64(15):5036-43. PubMed ID: 15289299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.